TRT and crown hair loss: what topical finasteride actually does
Quick answer
Exogenous testosterone administration raises serum DHT via 5-alpha reductase conversion, which can accelerate androgenetic alopecia in genetically predisposed men. Topical finasteride reduces scalp DHT with lower systemic exposure compared to the oral 1mg formulation, making it a clinically relevant option for TRT patients with AGA who want to minimize systemic DHT suppression. Any finasteride use, topical or oral, requires physician oversight given its hormonal mechanism and documented side effect profile.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @thathairlossexpert actually say?
The creator claims her husband's hair loss had been "stable for over 10 years" before he started testosterone replacement therapy (TRT). Three months into TRT, she says his crown visibly worsened, attributing this to TRT raising DHT levels. She then says they introduced "topical hair loss medication containing finasteride" to counteract the effect. No doses are mentioned, no physician is cited, and the video is essentially a before/after setup with a follow-up promised later in the week.
This is a personal anecdote, not a clinical study. That matters. One person's crown is not evidence of a universal mechanism, but the underlying biology she's describing is real and worth examining seriously.
Does the science back this up?
Mostly, yes. The TRT-to-DHT pathway she describes is biochemically accurate, and finasteride's mechanism makes it a logical intervention. But the timeline and degree of effect she implies deserve more scrutiny than she gives them.
Exogenous testosterone increases circulating DHT through conversion by the enzyme 5-alpha reductase, primarily in the scalp, prostate, and liver. This is well-established. TraishAM et al. (2011, Journal of Andrology) confirmed that supraphysiologic and even physiologic testosterone supplementation elevates serum DHT in hypogonadal men. DHT binds to androgen receptors in hair follicles and accelerates miniaturization in men with androgenetic alopecia (AGA), which is genetically determined sensitivity.
The key nuance she skips: TRT does not cause hair loss in men who lack genetic susceptibility. If her husband's hair was stable for a decade, it suggests his follicles have some androgen sensitivity already, and the extra DHT load from TRT likely crossed a threshold. That's a plausible clinical picture, but it's specific to him, not a guaranteed outcome for everyone on TRT.
What did they get wrong (or right)?
She got the core mechanism right. TRT raises DHT. DHT accelerates AGA in genetically susceptible individuals. Finasteride inhibits 5-alpha reductase and reduces DHT. These are not controversial claims.
Where she oversimplifies: she frames TRT as directly causing crown thinning without acknowledging that DHT-driven hair loss requires pre-existing genetic susceptibility. A man without AGA genetics on TRT is unlikely to go bald. She also doesn't distinguish between oral and topical finasteride, which have meaningfully different systemic absorption profiles. Topical finasteride (1% solution) reduces scalp DHT with less systemic DHT suppression than oral finasteride, per Caserini et al. (2016, Drug Delivery), which matters for men on TRT who may want to preserve some systemic DHT for libido and mood.
She also makes an implicit suggestion that her husband's experience is instructive for others on TRT. It may be, but the framing lacks the caveat that individual hormonal responses to TRT vary considerably depending on baseline testosterone, hematocrit, SHBG levels, and the specific testosterone formulation used.
What should you actually know?
If you're on TRT and noticing crown thinning, the mechanism she describes is real and worth discussing with a physician, not replicating from a TikTok video. A few things actually matter here.
First, finasteride in any form requires a prescription and carries documented side effects, including sexual dysfunction and mood changes in a subset of users. The incidence is debated, but the PCPT trial (Thompson et al., 2003, New England Journal of Medicine) and subsequent literature make clear this is not a zero-risk drug. Topical formulations may reduce systemic exposure but are not risk-free.
Second, not every man on TRT will experience accelerated hair loss. DHT levels post-TRT vary depending on dosing, ester type, and individual 5-alpha reductase activity. Regular monitoring of DHT alongside testosterone is something your prescribing physician should be doing anyway.
Third, the "counteract" framing she uses for finasteride is approximately correct mechanistically, but it's not a guaranteed fix. Finasteride stabilizes hair loss in the majority of men with AGA but does not regrow hair in all of them, and results on the crown are generally less robust than at the hairline, per Kaufman et al. (1998, Journal of the American Academy of Dermatology).
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For TRT and crown hair loss: what topical finasteride actually does, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
The human peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Anchor review for copper peptide gene-expression and tissue-repair claims.
PubMed
Effects of glycyl-histidyl-lysine-Cu on wound healing
Search-backed PubMed trail for wound-healing claims where specific topical versus injectable context matters.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
TRT and crown hair loss: what topical finasteride actually does is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
Exogenous testosterone administration raises serum DHT via 5-alpha reductase conversion, which can accelerate androgenetic alopecia in genetically predisposed men.
FormBlends verdict
Exogenous testosterone administration raises serum DHT via 5-alpha reductase conversion, which can accelerate androgenetic alopecia in genetically predisposed men. Topical finasteride reduces scalp DHT with lower systemic exposure compared to the oral 1mg formulation, making it a clinically relevant option for TRT patients with AGA who want to minimize systemic DHT suppression. Any finasteride use, topical or oral, requires physician oversight given its hormonal mechanism and documented side effect profile.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Exogenous testosterone administration raises serum DHT via 5-alpha reductase conversion, which can accelerate androgenetic alopecia in genetically predisposed men. Topical finasteride reduces scalp DHT with lower systemic exposure compared to the oral 1mg formulation, making it a clinically relevant option for TRT patients with AGA who want to minimize systemic DHT suppression. Any finasteride use, topical or oral, requires physician oversight given its hormonal mechanism and documented side effect profile.
- TRT raises serum DHT in most men: Traish et al. (2011, Journal of Andrology) confirmed this in hypogonadal men on testosterone therapy.
- DHT accelerates hair loss only in men with androgenetic alopecia genetics. TRT does not cause baldness in men without pre-existing follicle sensitivity.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- TRT raises serum DHT in most men: Traish et al. (2011, Journal of Andrology) confirmed this in hypogonadal men on testosterone therapy.
- DHT accelerates hair loss only in men with androgenetic alopecia genetics. TRT does not cause baldness in men without pre-existing follicle sensitivity.
- Topical finasteride (1% solution) reduces scalp DHT with lower systemic absorption than oral finasteride 1mg, per Caserini et al. (2016, Drug Delivery), which may matter for men on TRT.
- Finasteride's crown results are less predictable than hairline results. Kaufman et al. (1998, Journal of the American Academy of Dermatology) found vertex response rates were meaningful but not universal.
- Finasteride carries real side effect risks including sexual dysfunction and mood changes in a subset of users. It requires a physician prescription and monitoring, not self-directed use based on a TikTok video.
- DHT levels on TRT vary by testosterone ester, injection frequency, and individual 5-alpha reductase activity. Lab monitoring alongside clinical evaluation is the appropriate way to assess need for a DHT-blocking agent.
- One person's anecdotal response to topical finasteride after TRT-induced shedding is not a treatment protocol. See a physician who can review your hormone panel before making any changes.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Sophie That Hair Loss Expert · TikTok creator
2.8K views on this video
How TRT has affected my husband’s hair loss, specifically on his crown 👀 @Dense Hair Experts #finasteride #hairlossmedication #thathairlossexpert #topicalfinasteride
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Not medical advice. This video was made by Sophie That Hair Loss Expert, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.